title: Patients at high risk of invasive fungal infections: when and how to treat.
abstract: When and how to treat invasive fungal infections (IFIs) is discussed in this review, with a focus on the two most prevalent non-endemic IFIs, namely invasive aspergillosis and invasive candidiasis. Early treatment initiation in patients with IFIs has a profound impact on mortality rates, but reliable diagnostic measures are lacking. This situation has led to the parallel use of different treatment strategies, e.g. prophylaxis, empirical and pre-emptive treatment, as well as targeted treatment in response to a definite diagnosis of IFI. Identifying high-risk patients is the first step in reducing IFI-related mortality. Patients at risk of invasive aspergillosis comprise (i) those with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) during remission induction chemotherapy; (ii) patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT); (iii) recipients of solid organ transplants; and (iv) those with other conditions of severe and prolonged immunosuppression. Patients at high risk of invasive candidiasis are less well defined. Risk factors are diverse and include haematological malignancy, neutropenia, age <1 month or >65 years, and recent abdominal surgery. The individual risk further depends on the presence of a variety of other risk factors, including central venous catheters, use of broad spectrum antibacterials, prolonged intensive care unit (ICU) stay, total parenteral nutrition, mucosal Candida spp. colonization and renal failure.Extensive research has been conducted to facilitate the best possible treatment strategies for these severe infections. Optimal timing and choice of antifungal agents largely remain a matter of controversy. After having reviewed the major clinical trials, we conclude that comparisons between different treatment strategies cannot be made, neither at present nor in the near future. The complexity of the clinical problem leads to an eclectic treatment approach to reduce morbidity and mortality from IFIs without compromising tolerability. We recommend prophylaxis with posaconazole for allogeneic HSCT recipients, patients receiving induction chemotherapy for AML or MDS, and those undergoing immunosuppressive therapy for graft-versus-host disease after allogeneic HSCT. For the empirical treatment of persistently febrile neutropenia, caspofungin is our first- and liposomal amphotericin B deoxycholate (LAmB) our second-line choice. Once a diagnosis of invasive aspergillosis has been established, voriconazole should be the preferred treatment option, with LAmB being an alternative. Fluconazole prophylaxis for invasive candidiasis should remain restricted to high-risk ICU patients. Once a diagnosis has been established, the drug of choice for adequate treatment depends largely on neutrophil count and haemodynamic stability. In non-neutropenic patients, an echinocandin should be considered the first-line treatment option, while patients with susceptible Candida spp. may be switched to fluconazole. In neutropenic patients, caspofungin or micafungin might be preferred to anidulafungin as first-line treatment. LAmB is a second-line treatment option in both settings.Early diagnosis of IFIs is imperative to facilitate treatment success. In all patients at risk for IFIs, blood cultures, galactomannan antigen and diagnostic imaging should be rigorously enforced.
authors.affiliation: Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of the University of Cologne, Cologne, Germany.
authors.forename: Maria J G T
authors.initials: MJ
authors.lastname: Rüping
authors.forename: Jörg J
authors.initials: JJ
authors.lastname: Vehreschild
authors.forename: Oliver A
authors.initials: OA
authors.lastname: Cornely
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000473:pathology; D002177:Candidiasis / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D003422:Critical Care; D006801:Humans; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications; D012306:Risk
chemical_list: D000935:Antifungal Agents
references.citation: N Engl J Med. 2007 Jun 14;356(24):2472-82
references.pmid: 17568028
references.citation: J Infect Dis. 2000 Jan;181(1):309-16
references.pmid: 10608780
references.citation: Clin Infect Dis. 2000 Aug;31(2):545-53
references.pmid: 10987719
references.citation: Crit Care Med. 1999 Jun;27(6):1066-72
references.pmid: 10397206
references.citation: Transpl Infect Dis. 2007 Mar;9(1):3-10
references.pmid: 17313464
references.citation: N Engl J Med. 1994 Nov 17;331(20):1325-30
references.pmid: 7935701
references.citation: N Engl J Med. 1992 Mar 26;326(13):845-51
references.pmid: 1542320
references.citation: Am J Med. 1993 Aug;95(2):177-87
references.pmid: 8395142
references.citation: Drug Resist Updat. 2007 Jun;10(3):121-30
references.pmid: 17569573
references.citation: Clin Infect Dis. 2003 Jul 15;37(2):221-9
references.pmid: 12856215
references.citation: Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200
references.pmid: 17889356
references.citation: Clin Infect Dis. 2005 Nov 1;41(9):1242-50
references.pmid: 16206097
references.citation: J Clin Microbiol. 2007 Jun;45(6):1735-45
references.pmid: 17442797
references.citation: Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60
references.pmid: 16251295
references.citation: Clin Infect Dis. 2002 Apr 1;34(7):909-17
references.pmid: 11880955
references.citation: J Hosp Infect. 2002 Aug;51(4):288-96
references.pmid: 12183144
references.citation: Med Mycol. 2005 May;43(3):235-43
references.pmid: 16010850
references.citation: Infect Control Hosp Epidemiol. 2004 Aug;25(8):624-6
references.pmid: 15357151
references.citation: N Engl J Med. 2007 Jan 25;356(4):348-59
references.pmid: 17251531
references.citation: N Engl J Med. 2002 May 30;346(22):1745-7; author reply 1745-7
references.pmid: 12041526
references.citation: J Antimicrob Chemother. 2006 Apr;57(4):628-38
references.pmid: 16459344
references.citation: Lancet Infect Dis. 2003 Nov;3(11):685-702
references.pmid: 14592598
references.citation: Blood. 2003 May 1;101(9):3365-72
references.pmid: 12393455
references.citation: N Engl J Med. 2002 Jan 24;346(4):225-34
references.pmid: 11807146
references.citation: J Clin Microbiol. 2006 Jun;44(6):1977-81
references.pmid: 16757587
references.citation: Clin Infect Dis. 2006 Jul 1;43(1):25-31
references.pmid: 16758414
references.citation: Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):739-44
references.pmid: 15372315
references.citation: Blood. 2006 Nov 1;108(9):2928-36
references.pmid: 16720833
references.citation: Lancet. 2007 May 5;369(9572):1519-1527
references.pmid: 17482982
references.citation: Emerg Infect Dis. 2003 Aug;9(8):985-90
references.pmid: 12967498
references.citation: J Hosp Infect. 2002 Aug;51(4):297-304
references.pmid: 12183145
references.citation: J Infect. 2007 Nov;55(5):445-9
references.pmid: 17822770
references.citation: Clin Microbiol Infect. 2002 Jul;8(7):405-12
references.pmid: 12199850
references.citation: Clin Infect Dis. 2004 Feb 1;38(3):311-20
references.pmid: 14727199
references.citation: Crit Care. 2006;10(2):132
references.pmid: 16584528
references.citation: Clin Microbiol Rev. 2007 Jan;20(1):133-63
references.pmid: 17223626
references.citation: Clin Infect Dis. 1995 Nov;21(5):1077-89; quiz 1090-1
references.pmid: 8589125
references.citation: Liver Transpl. 2005 Jun;11(6):656-62
references.pmid: 15915482
references.citation: Clin Infect Dis. 1997 Jun;24(6):1122-8
references.pmid: 9195068
references.citation: N Engl J Med. 2002 Dec 19;347(25):2020-9
references.pmid: 12490683
references.citation: J Clin Microbiol. 2008 Mar;46(3):842-9
references.pmid: 18199791
references.citation: Clin Infect Dis. 2003 Nov 1;37(9):1172-7
references.pmid: 14557960
references.citation: N Engl J Med. 2002 Aug 8;347(6):408-15
references.pmid: 12167683
references.citation: Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-6
references.pmid: 17333081
references.citation: Clin Microbiol Infect. 2008 May;14 Suppl 4:65-70
references.pmid: 18430131
references.citation: Clin Infect Dis. 2008 Aug 1;47(3):427; author reply 427-8
references.pmid: 18605908
references.citation: J Clin Microbiol. 2004 Jul;42(7):3142-6
references.pmid: 15243073
references.citation: Clin Infect Dis. 2002 Jan 1;34(1):7-14
references.pmid: 11731939
references.citation: Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5
references.pmid: 15229094
references.citation: Intensive Care Med. 2002 Dec;28(12):1708-17
references.pmid: 12447512
references.citation: Transpl Infect Dis. 1999 Dec;1(4):229-36
references.pmid: 11428994
references.citation: J Infect Dis. 1995 Jun;171(6):1545-52
references.pmid: 7769290
references.citation: J Clin Microbiol. 2006 Mar;44(3):760-3
references.pmid: 16517851
references.citation: Crit Care Med. 2003 Mar;31(3):752-7
references.pmid: 12626979
references.citation: J Heart Lung Transplant. 2003 Mar;22(3):258-66
references.pmid: 12633692
references.citation: Clin Infect Dis. 2004 Nov 15;39(10):1407-16
references.pmid: 15546073
references.citation: J Infect Dis. 2002 Nov 1;186(9):1297-306
references.pmid: 12402199
references.citation: Ann Intern Med. 2001 Sep 18;135(6):412-22
references.pmid: 11560454
references.citation: N Engl J Med. 2007 Jan 25;356(4):335-47
references.pmid: 17251530
references.citation: J Antimicrob Chemother. 2005 Sep;56(3):532-7
references.pmid: 16040623
references.citation: Emerg Infect Dis. 2004 Oct;10(10):1713-20
references.pmid: 15504255
references.citation: J Clin Microbiol. 2004 Apr;42(4):1519-27
references.pmid: 15070998
references.citation: Arch Surg. 1971 May;102(5):476-82
references.pmid: 5580338
references.citation: Blood. 2002 May 15;99(10):3554-61
references.pmid: 11986207
references.citation: Am J Med. 1994 Aug;97(2):135-44
references.pmid: 8059779
references.citation: J Clin Microbiol. 2005 Apr;43(4):1829-35
references.pmid: 15815004
references.citation: N Engl J Med. 2004 Sep 30;351(14):1391-402
references.pmid: 15459300
references.citation: Clin Infect Dis. 2008 Feb 1;46(3):327-60
references.pmid: 18177225
references.citation: J Clin Microbiol. 2002 Apr;40(4):1298-302
references.pmid: 11923348
references.citation: Crit Care. 2006 Feb;10(1):R31
references.pmid: 16507158
references.citation: Arch Surg. 1991 Jan;126(1):44-8
references.pmid: 1985634
references.citation: Clin Infect Dis. 2001 Apr 15;32(8):1191-200
references.pmid: 11283809
references.citation: Br J Haematol. 2005 Oct;131(1):22-8
references.pmid: 16173959
references.citation: Antimicrob Agents Chemother. 2007 May;51(5):1818-21
references.pmid: 17307977
references.citation: Clin Infect Dis. 1999 Nov;29(5):1164-70
references.pmid: 10524958
references.citation: Br J Haematol. 2002 Feb;116(2):475-82
references.pmid: 11841455
references.citation: N Engl J Med. 2007 Dec 20;357(25):2601-14
references.pmid: 18094380
references.citation: Ann Surg. 1994 Dec;220(6):751-8
references.pmid: 7986142
references.citation: Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):457-62
references.pmid: 12898283
references.citation: J Clin Microbiol. 2006 Feb;44(2):529-35
references.pmid: 16455909
references.citation: Am J Transplant. 2004 Nov;4 Suppl 10:110-34
references.pmid: 15504225
references.citation: Clin Microbiol Rev. 2005 Jan;18(1):44-69
references.pmid: 15653818
references.citation: Radiology. 1985 Dec;157(3):611-4
references.pmid: 3864189
references.citation: Crit Care Med. 2006 Mar;34(3):730-7
references.pmid: 16505659
references.citation: Clin Infect Dis. 2001 Jul 15;33(2):177-86
references.pmid: 11418877
references.citation: Liver Transpl. 2002 Nov;8(11):1065-70
references.pmid: 12424722
references.citation: Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5
references.pmid: 9564455
references.citation: Clin Infect Dis. 2007 Oct 1;45(7):883-93
references.pmid: 17806055
references.citation: Intensive Care Med. 2007 Oct;33(10):1679-81
references.pmid: 17646965
references.citation: N Engl J Med. 2002 Jan 24;346(4):278-80
references.pmid: 11807153
references.citation: Clin Infect Dis. 2005 Jul 1;41(1):52-9
references.pmid: 15937763
references.citation: J Trauma. 1979 Oct;19(10):765-7
references.pmid: 490691
references.citation: Diagn Microbiol Infect Dis. 2008 Mar;60(3):273-7
references.pmid: 18024053
references.citation: Expert Opin Pharmacother. 2008 Feb;9(2):175-91
references.pmid: 18201143
references.citation: Lancet. 2005 Oct 22-28;366(9495):1435-42
references.pmid: 16243088
references.citation: Blood. 2001 Mar 15;97(6):1604-10
references.pmid: 11238098
references.citation: Blood. 2002 Dec 15;100(13):4358-66
references.pmid: 12393425
references.citation: Haematologica. 2006 Aug;91(8):1068-75
references.pmid: 16885047
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
references.pmid: 16127033
references.citation: N Engl J Med. 1999 Mar 11;340(10):764-71
references.pmid: 10072411
references.citation: Curr Opin Infect Dis. 2006 Dec;19(6):571-6
references.pmid: 17075333
references.citation: Drugs. 2007;67(11):1567-601
references.pmid: 17661528
references.citation: Clin Infect Dis. 2007 May 15;44(10):1289-97
references.pmid: 17443465
references.citation: Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):797-804
references.pmid: 7889948
references.citation: Ann Surg. 2001 Apr;233(4):542-8
references.pmid: 11303137
references.citation: Medicine (Baltimore). 2000 Jul;79(4):250-60
references.pmid: 10941354
references.citation: J Clin Microbiol. 2004 Jan;42(1):435-8
references.pmid: 14715799
references.citation: Clin Infect Dis. 1993 May;16(5):677-88
references.pmid: 8507760
references.citation: Ann Hematol. 2003 Oct;82 Suppl 2:S118-26
references.pmid: 13680172
references.citation: J Clin Microbiol. 2005 Sep;43(9):4434-40
references.pmid: 16145088
references.citation: Clin Diagn Lab Immunol. 2003 Sep;10(5):882-5
references.pmid: 12965921
references.citation: Br J Haematol. 2006 Jan;132(1):3-12
references.pmid: 16371014
references.citation: Lancet Infect Dis. 2003 Mar;3(3):156-61
references.pmid: 12614732
references.citation: J Antimicrob Chemother. 2003 Jul;52(1):71-7
references.pmid: 12775680
references.citation: Clin Infect Dis. 2004 Aug 1;39(3):309-17
references.pmid: 15306996
references.citation: Clin Infect Dis. 2003 Sep 1;37(5):634-43
references.pmid: 12942393
references.citation: Liver Transpl. 2006 May;12(5):850-8
references.pmid: 16628697
references.citation: Ann Hematol. 2003 Oct;82 Suppl 2:S105-17
references.pmid: 13680173
references.citation: J Infect. 1991 Jan;22(1):45-52
references.pmid: 1848268
references.citation: Medicine (Baltimore). 2003 Sep;82(5):309-21
references.pmid: 14530780
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):955-63
references.pmid: 16511759
references.citation: Crit Care Med. 2004 Dec;32(12):2443-9
references.pmid: 15599149
references.citation: Intensive Care Med. 2005 Nov;31(11):1479-87
references.pmid: 16172847
references.citation: Diagn Microbiol Infect Dis. 1999 Aug;34(4):281-6
references.pmid: 10459478
references.citation: J Clin Microbiol. 2002 Sep;40(9):3489-92
references.pmid: 12202600
references.citation: Am J Transplant. 2004 May;4(5):796-802
references.pmid: 15084177
references.citation: J Antimicrob Chemother. 2006 Feb;57(2):317-25
references.pmid: 16339606
references.citation: Clin Infect Dis. 2005 Sep 15;41 Suppl 6:S389-93
references.pmid: 16108005
references.citation: Clin Infect Dis. 2001 Oct 15;33(8):e83-90
references.pmid: 11550120
references.citation: Transplantation. 2004 Apr 27;77(8):1260-4
references.pmid: 15114095
references.citation: Surg Infect (Larchmt). 2003 Winter;4(4):345-54
references.pmid: 15012861
references.citation: Clin Infect Dis. 2008 Jun 15;46(12):1813-21
references.pmid: 18462102
references.citation: Clin Infect Dis. 2007 Feb 1;44(3):373-9
references.pmid: 17205443
references.citation: Antimicrob Agents Chemother. 2005 Feb;49(2):512-7
references.pmid: 15673726
references.citation: Arch Intern Med. 1989 Oct;149(10):2349-53
references.pmid: 2802900
references.citation: Lancet Infect Dis. 2005 Oct;5(10):609-22
references.pmid: 16183515